Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | MITF | O75030 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.61 |
| ▸ | MYC | P01106 | 2/20 | 0.61 |
| ▸ | MAX | P61244 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | FABP4 | P15090 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008632 | 0.93 | FFAR1 (0.74) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL17319529 | 0.88 | PTPN12 (0.72) | MAPTALDH1A1KMT2AHTTAKR1B1 | |
| SCHEMBL14905165 | 0.87 | CISD1 (0.79) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL12008748 | 0.87 | CISD1 (0.79) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL12008768 | 0.87 | CISD1 (0.79) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL12008493 | 0.85 | CISD1 (0.81) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL15709015 | 0.85 | CISD1 (0.81) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL18420883 | 0.85 | CISD1 (0.81) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL12008711 | 0.85 | CISD1 (0.81) | CISD1MAOAMAPTNCOA3ALDH1A1 | |
| SCHEMBL6887096 | 0.85 | MAPT (0.78) | CISD1MAOAMAPTNCOA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | CISD1 2475/4885MAOA 4320/4885MAPT 2143/4885 |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | CTNNB1, CTNNA1, CTNNBL1 | CISD1 2618/4885MAOA 3935/4885MAPT 1929/4885 |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | CISD1 2618/4885MAOA 3935/4885MAPT 1929/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | CISD1 2618/4885MAOA 3935/4885MAPT 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.